These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 33383214)

  • 41. Higher Tumor Burden Neutralizes Negative Margin Status in Hepatectomy for Colorectal Cancer Liver Metastasis.
    Oshi M; Margonis GA; Sawada Y; Andreatos N; He J; Kumamoto T; Morioka D; Wolfgang CL; Tanaka K; Weiss MJ; Endo I
    Ann Surg Oncol; 2019 Feb; 26(2):593-603. PubMed ID: 30483976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
    Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognosis of Synchronous Colorectal Liver Metastases After Simultaneous Curative-Intent Surgery According to Primary Tumor Location and KRAS Mutational Status.
    Kim HS; Lee JM; Kim HS; Yang SY; Han YD; Cho MS; Hur H; Min BS; Lee KY; Kim NK
    Ann Surg Oncol; 2020 Dec; 27(13):5150-5158. PubMed ID: 32812112
    [TBL] [Abstract][Full Text] [Related]  

  • 44. From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis.
    Andreatos N; Ronnekleiv-Kelly S; Margonis GA; Sasaki K; Gani F; Amini N; Wilson A; Pawlik TM
    Surg Oncol; 2016 Sep; 25(3):332-8. PubMed ID: 27566041
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic value of the combination of primary tumor location and RAS mutational status on patients with colorectal liver metastasis undergoing hepatectomy.
    Yan XL; Wang K; Bao Q; Wang HW; Jin KM; Su YM; Xing BC
    J Surg Oncol; 2022 May; 125(6):1002-1012. PubMed ID: 35171534
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
    Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A
    Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RAS mutation associated with short surgically controllable period in colorectal liver metastases: a retrospective study.
    Ito S; Takamoto T; Nara S; Ban D; Mizui T; Nagata H; Takamizawa Y; Moritani K; Tsukamoto S; Kanemitsu Y; Kinugasa Y; Esaki M
    World J Surg Oncol; 2024 Sep; 22(1):247. PubMed ID: 39267117
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Time to Surgery of Colorectal Liver Metastases on Survival.
    Chen EY; Mayo SC; Sutton T; Kearney MR; Kardosh A; Vaccaro GM; Billingsley KG; Lopez CD
    J Gastrointest Cancer; 2021 Mar; 52(1):169-176. PubMed ID: 32086781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases.
    Pikoulis E; Margonis GA; Andreatos N; Sasaki K; Angelou A; Polychronidis G; Pikouli A; Riza E; Pawlik TM; Antoniou E
    Anticancer Res; 2016 Sep; 36(9):4805-11. PubMed ID: 27630332
    [TBL] [Abstract][Full Text] [Related]  

  • 50. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.
    Kemeny NE; Chou JF; Capanu M; Gewirtz AN; Cercek A; Kingham TP; Jarnagin WR; Fong YC; DeMatteo RP; Allen PJ; Shia J; Ang C; Vakiani E; D'Angelica MI
    Cancer; 2014 Dec; 120(24):3965-71. PubMed ID: 25155157
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anatomical resection improves relapse-free survival in colorectal liver metastases in patients with KRAS/NRAS/BRAF mutations or right-sided colon cancer: a retrospective cohort study.
    Chang W; Chen Y; Zhou S; Ren L; Xu Y; Zhu D; Tang W; Ye Q; Wang X; Fan J; Wei Y; Xu J
    Int J Surg; 2023 Oct; 109(10):3070-3077. PubMed ID: 37526097
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The prognosis of colorectal cancer liver metastases associated with inflammatory bowel disease: An exploratory analysis.
    Margonis GA; Buettner S; Andreatos N; Wagner D; Sasaki K; Galjart B; Kamphues C; Pawlik TM; Poultsides G; Kaczirek K; Lønning PE; Verhoef C; Kreis ME; Wolfgang CL; Weiss MJ
    J Surg Oncol; 2018 Dec; 118(7):1074-1080. PubMed ID: 30261094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
    Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
    J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Construction and validation of "WCH-nomogram" for predicting the prognosis after resection of colorectal liver metastases.
    Jiang C; Liu W; Jin Z; Lan L; Xu L; Du A; Peng S; Zeng Y; Wang H; Liao M; Zhou J
    Cancer Med; 2024 May; 13(9):e7222. PubMed ID: 38698687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy.
    Liang JY; Xi SY; Shao Q; Yuan YF; Li BK; Zheng Y; Wang DS; Wu XJ; Ding PR; Chen G; Li LR; Wang FH; Wang ZQ; Pan ZZ; Xu RH; Li YH
    Cancer Immunol Immunother; 2020 Dec; 69(12):2623-2634. PubMed ID: 32601799
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status: A Study By the International Genetic Consortium for Colorectal Liver Metastasis.
    Margonis GA; Amini N; Buettner S; Kim Y; Wang J; Andreatos N; Wagner D; Sasaki K; Beer A; Kamphues C; Morioka D; Løes IM; Imai K; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Burkhart R; Endo I; Baba H; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    Ann Surg; 2021 Jun; 273(6):1165-1172. PubMed ID: 31389831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial.
    Lueong SS; Herbst A; Liffers ST; Bielefeld N; Horn PA; Tannapfel A; Reinacher-Schick A; Hinke A; Hegewisch-Becker S; Kolligs FT; Siveke JT
    Clin Chem; 2020 Dec; 66(12):1510-1520. PubMed ID: 33257977
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis.
    Sasaki K; Andreatos N; Margonis GA; He J; Weiss M; Johnston F; Wolfgang C; Antoniou E; Pikoulis E; Pawlik TM
    J Surg Oncol; 2016 Dec; 114(7):803-809. PubMed ID: 27792291
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis.
    Zhang Y; Wang Y; Yuan Y; Qiu J; Qiu Y; He W; Zheng Y; Wang Z; Gu Y; Lu Z; Chen G; Ding P; Wu X; Pan Z; Wan D; Li Y; Xu R; Yuan Y; Li B
    World J Surg Oncol; 2020 May; 18(1):98. PubMed ID: 32423450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
    Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
    J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.